Developing infant nutrition products is a costly and time-consuming business. NIZO’s MicroColon model offers companies a solution to pre-screen ingredients, early in the development process. But could it be further optimised for the needs of infant nutrition companies? Guus explains this during this short video.
The market for probiotics and live biotherapeutic products continues to grow, as we increase our understanding of how they can improve health. Probiotic and pharmaceutical companies are looking for ways to use the naturally occurring bacteria in our bodies to amend dysbiosis of the gut, skin and more. Then they must get their products to market, quickly and cost-effectively. But there are many challenges that will define a company’s success or failure – especially when working with living organisms, that don’t always behave the way we want. In this webcast, NIZO's multidisciplinary and multi-stage approach in the probiotic journey, from discovery to health benefit substantiation, will be explained.
NIZO supports a healthy lifestyle by substantiating health benefits of food. In this video, Marjolijn Bragt of FrieslandCampina talks about her collaboration with @NIZO in an integrated approach to build a convincing case, in which the scientific and regulatory guidance, targeted preclinical studies, well-designed clinical trials, biomarker analysis and expert interpretation are combined.
NIZO supports a healthy lifestyle by substantiating health benefits of food. In this video, Ruud Albers, CEO of Nutrileads talks about his collaboration with NIZO in an integrated approach to build a convincing case, in which the scientific and regulatory guidance, targeted preclinical studies, well-designed clinical trials, biomarker analysis and expert interpretation are combined.
Validate the impact of your food ingredient on infection resistance and immune response with fewer participants and in a shorter timeframe using challenge studies
Consumers around the world are looking for foods that boost their infection resistance and immune response. This has led to steady growth in new products that offer immune health benefits, but these claims need to be supported by evidence.
Clinical trials offer a scientifically validated approach for substantiating the infection resistance or immune response claim of your ingredient. However, relying on ‘natural’ exposure to pathogens can significantly extend the timeframe of your study and increase the number of participants needed. It also increases the risk that volunteers will not conform to the study specifications or will drop out altogether.
By inducing symptoms or disturbing the physiological balance through the introduction of a controlled ‘stressor’, you can speed up validation, while requiring fewer participants. So you can get your food immune health claim substantiated more quickly and cost-efficiently.
Depending on the type of health benefit you want to validate, NIZO can design and coordinate the execution of an infection resistance or immunity benefit study on your ingredient, in line with the requirements of the European Food Safety Authority (EFSA). For example:
At NIZO, we have unique expertise in infection resistance and immune response challenge models that incorporate a ‘stressor’. For infection resistance, we have developed our own human model for E. coli studies. For immune response challenge studies, we use commercially available cholera and hepatitis B vaccines.
We maintain full control over the stressor, its dose and its timing. These studies include a control group and are conducted double blind.
Our infection resistance and immune response studies: